Stock Report

All about this stock under one free report Last Updated: 17-May-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Longboard Pharmaceuticals Inc. (LBPH)

Stock Card factsheet share-fund-plan-icon

$59.98

$0.00 (0.00%)

As on 13-Dec-2024 09:30EDT

Market cap

info icon

$2,342 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

8.5

Div. Yield

info icon

0 %

Longboard Pharmaceuticals (LBPH) Share Price

Compare

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 59.98 High: 59.98

52 Week Range

Low: -- High: --

Liquidityliquidity

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $0 Mln

  • ROEROE information

    -0.5 %

  • ROCEROCE information

    -- %

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    -12.3

  • Debt to EquityDebt to Equity information

    0

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $-2.2

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    34,436,200

Years Aggregate

CFO

$--

EBITDA

$--

Net Profit

$--

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Longboard Pharmaceuticals (LBPH)
894.7 0.4 80.3 1,173.5 115.9 -- --
BSE Sensex*
-11.1 -2.1 -8.9 -7.5 6.6 9.1 11.4
S&P Small-Cap 600#
-5.8 -5.3 -13.7 -6.3 5.3 3.0 5.5
As on 13-Dec-2024  |  *As on 15-May-2026  |  #As on 26-Oct-2023
Company
2023
2022
Longboard Pharmaceuticals (LBPH)
85.0 -33.2
S&P Small-Cap 600
13.9 -17.4
BSE Sensex
18.7 4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
Quarterly Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Annual

*All values are in ($ Mln)

Key Ratios

View Details

5Y Avg -- 3Y Avg -- TTM --

P/E Ratio

--

--Min --Median --Max

P/B Ratio

--

--Min --Median --Max

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

Peers

View Details
Company
 Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Longboard Pharmaceuticals (LBPH)
60.0 2,342.0 0.0 -76.3 -1,093,125.0 -25.9 -- 8.5
Lumos Pharma (LUMO)
4.3 37.5 2.2 -34.9 -1,302.3 -312.4 -- 7.6
Pieris Pharmaceuticals (PIRS)
13.3 21.1 1.4 -16.0 -1,156.1 -83.5 -- 1.1
Virios Therapeutics (VIRI)
2.7 0.2 0.0 -4.7 -- -134.8 -- 3.3

Shareholding Pattern

View Details
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

About Longboard Pharmaceuticals (LBPH)

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial...  for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California. As of December 2, 2024, Longboard Pharmaceuticals, Inc. operates as a subsidiary of Langkawi Corporation.  Read more

  • President, CEO, Secretary & Director

    Mr. Kevin R. Lind

  • President, CEO, Secretary & Director

    Mr. Kevin R. Lind

  • Headquarters

    La Jolla, CA

  • Website

    https://www.longboardpharma.com

Value Research Ratings

Our rating system has guided millions of investors in the past 20 years.

Top Rated Stocks

All stocks with 5-star Value Research Ratings

Top Rated Stocks Icon

High Quality Small Caps

Small-cap stocks rated high on quality score

High Quality Small Caps Icon

High Growth Large Caps

Large-cap stocks with a high growth score

High Growth Large Caps Icon

Value Meets Momentum

Top momentum stocks with a high valuation score

Value Meets Momentum Icon

Top Rated Banks

Banks that rate high on Value Research Stock Ratings

Top Rated Banks Icon
Explore Screeners
Edit peer-selector-edit

FAQs for Longboard Pharmaceuticals (LBPH)

The share price of Longboard Pharmaceuticals Inc (LBPH) is $59.98 (NASDAQ) as of 13-Dec-2024 09:30 EDT. Longboard Pharmaceuticals Inc (LBPH) has given a return of 115.9% in the last 3 years.

Since, TTM earnings of Longboard Pharmaceuticals Inc (LBPH) is negative, P/E ratio is not available.
The P/B ratio of Longboard Pharmaceuticals Inc (LBPH) is 8.51 times as on 13-Dec-2024, a 90 premium to its peers’ median range of 4.49 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2023
-2.65
3.53
2022
-1.30
0.91
2021
-3.00
0.80
2020
--
--
2023
-2.65
3.53

The 52-week high and low of Longboard Pharmaceuticals Inc (LBPH) are Rs -- and Rs -- as of 17-May-2026.

Longboard Pharmaceuticals Inc (LBPH) has a market capitalisation of $ 2,342 Mln as on 13-Dec-2024. As per SEBI classification, it is a Small Cap company.

Before investing in Longboard Pharmaceuticals Inc (LBPH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.